Jennison Associates LLC boosted its position in Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 29.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 377,894 shares of the company's stock after acquiring an additional 86,399 shares during the quarter. Jennison Associates LLC owned 0.64% of Twist Bioscience worth $17,073,000 at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of TWST. State Board of Administration of Florida Retirement System grew its holdings in shares of Twist Bioscience by 14.8% during the first quarter. State Board of Administration of Florida Retirement System now owns 18,649 shares of the company's stock worth $640,000 after purchasing an additional 2,410 shares during the last quarter. Edgestream Partners L.P. acquired a new position in Twist Bioscience in the 1st quarter valued at approximately $242,000. American International Group Inc. lifted its holdings in shares of Twist Bioscience by 0.8% during the first quarter. American International Group Inc. now owns 28,506 shares of the company's stock worth $978,000 after purchasing an additional 213 shares during the period. PEAK6 Investments LLC increased its holdings in Twist Bioscience by 20.7% in the first quarter. PEAK6 Investments LLC now owns 14,000 shares of the company's stock valued at $480,000 after purchasing an additional 2,400 shares during the period. Finally, Magnetar Financial LLC acquired a new position in Twist Bioscience during the 1st quarter worth about $389,000.
Shares of NASDAQ TWST opened at $42.23 on Friday. The stock's 50 day moving average price is $43.88 and its 200-day moving average price is $46.12. Twist Bioscience Co. has a twelve month low of $23.07 and a twelve month high of $60.90.
In other news, CAO Robert F. Werner sold 1,448 shares of Twist Bioscience stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total value of $64,580.80. Following the completion of the transaction, the chief accounting officer now owns 45,620 shares in the company, valued at $2,034,652. This trade represents a 3.08 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Paula Green sold 3,310 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $43.21, for a total transaction of $143,025.10. Following the completion of the transaction, the senior vice president now owns 84,585 shares of the company's stock, valued at $3,654,917.85. This represents a 3.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 98,118 shares of company stock valued at $4,391,151. Insiders own 3.92% of the company's stock.
TWST has been the topic of a number of recent analyst reports. Scotiabank lifted their price objective on Twist Bioscience from $50.00 to $54.00 and gave the stock a "sector outperform" rating in a research note on Tuesday. Barclays lowered their target price on shares of Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating for the company in a research note on Tuesday. JPMorgan Chase & Co. upped their price target on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an "underweight" rating in a research report on Monday, August 5th. Robert W. Baird boosted their price objective on Twist Bioscience from $46.00 to $48.00 and gave the company an "outperform" rating in a research note on Tuesday. Finally, Leerink Partners lifted their target price on Twist Bioscience from $45.00 to $48.00 and gave the stock a "market perform" rating in a report on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, Twist Bioscience presently has an average rating of "Moderate Buy" and an average price target of $51.78.
Check Out Our Latest Research Report on TWST
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Before you consider Twist Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Twist Bioscience wasn't on the list.
While Twist Bioscience currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.